An open-label, rater-blinded, 8-week trial of bupropion hydrochloride extended-release in patients with major depressive disorder with atypical features

H. J. Seo, B. C. Lee, J. H. Seok, H. J. Jeon, J. W. Paik, W. Kim, K. P. Kwak, Changsu Han, K. U. Lee, C. U. Pae

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objectives: The present study aimed at investigating the effectiveness and tolerability of sbupropion hydrochloride extended release (XL) in major depressive disorder (MDD) patients with atypical features (AF). Methods: 51 patients were prescribed bupropion XL for 8 weeks (6 visits: screening, baseline, weeks 1, 2, 4 and 8). The primary efficacy measure was a change of the Structured Interview Guide for the Hamilton Depression Rating Scale-Seasonal Affective Disorder Version (SIGH-SAD) from baseline to endpoint. Secondary efficacy measures included the SIGH-SAD atypical symptoms subscale, Clinical Global Impression-Severity (CGI-S), Sheehan Disability Scale (SDS) and Epworth Sleepiness Questionnaire (ESQ). Response or remission was defined as ≥50% reduction or ≤7 in SIGH-SAD total scores, respectively, at end of treatment. Results: The HAM-D-29 total score reduced by 55.3% from baseline (27.3±6.5) to end of treatment (12.2±6.3) (p<0.001). Atypical symptom subscale scores also reduced by 54.5% from baseline (9.2±3.0) to end of treatment (4.2±2.8) (p<0.001). At the end of treatment, 24.4% (n=10) and 51.2% (n=21) subjects were classified as remitters and responders, respectively. The most frequently reported AEs were headache (13.7%), dry mouth (11.8%), dizziness (9.8%), and dyspepsia (9.8%). Conclusions: Our preliminary study indicates that bupropion XL may be beneficial in the treatment of MDD with atypical features. Adequately powered, randomized, double-blind, placebo-controlled trials are necessary to determine our results.

Original languageEnglish
Pages (from-to)221-226
Number of pages6
JournalPharmacopsychiatry
Volume46
Issue number6
DOIs
Publication statusPublished - 2013 Aug 23

Fingerprint

Bupropion
Major Depressive Disorder
Seasonal Affective Disorder
Therapeutics
Dyspepsia
Dizziness
Headache
Mouth
Placebos
Interviews
Depression

Keywords

  • atypical depression
  • bupropion XL
  • effectiveness
  • remission
  • response
  • tolerability

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

An open-label, rater-blinded, 8-week trial of bupropion hydrochloride extended-release in patients with major depressive disorder with atypical features. / Seo, H. J.; Lee, B. C.; Seok, J. H.; Jeon, H. J.; Paik, J. W.; Kim, W.; Kwak, K. P.; Han, Changsu; Lee, K. U.; Pae, C. U.

In: Pharmacopsychiatry, Vol. 46, No. 6, 23.08.2013, p. 221-226.

Research output: Contribution to journalArticle

Seo, H. J. ; Lee, B. C. ; Seok, J. H. ; Jeon, H. J. ; Paik, J. W. ; Kim, W. ; Kwak, K. P. ; Han, Changsu ; Lee, K. U. ; Pae, C. U. / An open-label, rater-blinded, 8-week trial of bupropion hydrochloride extended-release in patients with major depressive disorder with atypical features. In: Pharmacopsychiatry. 2013 ; Vol. 46, No. 6. pp. 221-226.
@article{f373aa659b78407494bd262cf1af06ed,
title = "An open-label, rater-blinded, 8-week trial of bupropion hydrochloride extended-release in patients with major depressive disorder with atypical features",
abstract = "Objectives: The present study aimed at investigating the effectiveness and tolerability of sbupropion hydrochloride extended release (XL) in major depressive disorder (MDD) patients with atypical features (AF). Methods: 51 patients were prescribed bupropion XL for 8 weeks (6 visits: screening, baseline, weeks 1, 2, 4 and 8). The primary efficacy measure was a change of the Structured Interview Guide for the Hamilton Depression Rating Scale-Seasonal Affective Disorder Version (SIGH-SAD) from baseline to endpoint. Secondary efficacy measures included the SIGH-SAD atypical symptoms subscale, Clinical Global Impression-Severity (CGI-S), Sheehan Disability Scale (SDS) and Epworth Sleepiness Questionnaire (ESQ). Response or remission was defined as ≥50{\%} reduction or ≤7 in SIGH-SAD total scores, respectively, at end of treatment. Results: The HAM-D-29 total score reduced by 55.3{\%} from baseline (27.3±6.5) to end of treatment (12.2±6.3) (p<0.001). Atypical symptom subscale scores also reduced by 54.5{\%} from baseline (9.2±3.0) to end of treatment (4.2±2.8) (p<0.001). At the end of treatment, 24.4{\%} (n=10) and 51.2{\%} (n=21) subjects were classified as remitters and responders, respectively. The most frequently reported AEs were headache (13.7{\%}), dry mouth (11.8{\%}), dizziness (9.8{\%}), and dyspepsia (9.8{\%}). Conclusions: Our preliminary study indicates that bupropion XL may be beneficial in the treatment of MDD with atypical features. Adequately powered, randomized, double-blind, placebo-controlled trials are necessary to determine our results.",
keywords = "atypical depression, bupropion XL, effectiveness, remission, response, tolerability",
author = "Seo, {H. J.} and Lee, {B. C.} and Seok, {J. H.} and Jeon, {H. J.} and Paik, {J. W.} and W. Kim and Kwak, {K. P.} and Changsu Han and Lee, {K. U.} and Pae, {C. U.}",
year = "2013",
month = "8",
day = "23",
doi = "10.1055/s-0033-1353171",
language = "English",
volume = "46",
pages = "221--226",
journal = "Pharmacopsychiatry",
issn = "0176-3679",
publisher = "Georg Thieme Verlag",
number = "6",

}

TY - JOUR

T1 - An open-label, rater-blinded, 8-week trial of bupropion hydrochloride extended-release in patients with major depressive disorder with atypical features

AU - Seo, H. J.

AU - Lee, B. C.

AU - Seok, J. H.

AU - Jeon, H. J.

AU - Paik, J. W.

AU - Kim, W.

AU - Kwak, K. P.

AU - Han, Changsu

AU - Lee, K. U.

AU - Pae, C. U.

PY - 2013/8/23

Y1 - 2013/8/23

N2 - Objectives: The present study aimed at investigating the effectiveness and tolerability of sbupropion hydrochloride extended release (XL) in major depressive disorder (MDD) patients with atypical features (AF). Methods: 51 patients were prescribed bupropion XL for 8 weeks (6 visits: screening, baseline, weeks 1, 2, 4 and 8). The primary efficacy measure was a change of the Structured Interview Guide for the Hamilton Depression Rating Scale-Seasonal Affective Disorder Version (SIGH-SAD) from baseline to endpoint. Secondary efficacy measures included the SIGH-SAD atypical symptoms subscale, Clinical Global Impression-Severity (CGI-S), Sheehan Disability Scale (SDS) and Epworth Sleepiness Questionnaire (ESQ). Response or remission was defined as ≥50% reduction or ≤7 in SIGH-SAD total scores, respectively, at end of treatment. Results: The HAM-D-29 total score reduced by 55.3% from baseline (27.3±6.5) to end of treatment (12.2±6.3) (p<0.001). Atypical symptom subscale scores also reduced by 54.5% from baseline (9.2±3.0) to end of treatment (4.2±2.8) (p<0.001). At the end of treatment, 24.4% (n=10) and 51.2% (n=21) subjects were classified as remitters and responders, respectively. The most frequently reported AEs were headache (13.7%), dry mouth (11.8%), dizziness (9.8%), and dyspepsia (9.8%). Conclusions: Our preliminary study indicates that bupropion XL may be beneficial in the treatment of MDD with atypical features. Adequately powered, randomized, double-blind, placebo-controlled trials are necessary to determine our results.

AB - Objectives: The present study aimed at investigating the effectiveness and tolerability of sbupropion hydrochloride extended release (XL) in major depressive disorder (MDD) patients with atypical features (AF). Methods: 51 patients were prescribed bupropion XL for 8 weeks (6 visits: screening, baseline, weeks 1, 2, 4 and 8). The primary efficacy measure was a change of the Structured Interview Guide for the Hamilton Depression Rating Scale-Seasonal Affective Disorder Version (SIGH-SAD) from baseline to endpoint. Secondary efficacy measures included the SIGH-SAD atypical symptoms subscale, Clinical Global Impression-Severity (CGI-S), Sheehan Disability Scale (SDS) and Epworth Sleepiness Questionnaire (ESQ). Response or remission was defined as ≥50% reduction or ≤7 in SIGH-SAD total scores, respectively, at end of treatment. Results: The HAM-D-29 total score reduced by 55.3% from baseline (27.3±6.5) to end of treatment (12.2±6.3) (p<0.001). Atypical symptom subscale scores also reduced by 54.5% from baseline (9.2±3.0) to end of treatment (4.2±2.8) (p<0.001). At the end of treatment, 24.4% (n=10) and 51.2% (n=21) subjects were classified as remitters and responders, respectively. The most frequently reported AEs were headache (13.7%), dry mouth (11.8%), dizziness (9.8%), and dyspepsia (9.8%). Conclusions: Our preliminary study indicates that bupropion XL may be beneficial in the treatment of MDD with atypical features. Adequately powered, randomized, double-blind, placebo-controlled trials are necessary to determine our results.

KW - atypical depression

KW - bupropion XL

KW - effectiveness

KW - remission

KW - response

KW - tolerability

UR - http://www.scopus.com/inward/record.url?scp=84884280416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884280416&partnerID=8YFLogxK

U2 - 10.1055/s-0033-1353171

DO - 10.1055/s-0033-1353171

M3 - Article

VL - 46

SP - 221

EP - 226

JO - Pharmacopsychiatry

JF - Pharmacopsychiatry

SN - 0176-3679

IS - 6

ER -